First, a brief history of time in the Europe Union (EU). It goes slowly. That's it! For the last two years or so the European Commission has been consulting on plans to revise the European Clinical Trials Directive. The Directive has been in force since 2001. Researchers hate it. To be fair so do many … Continue reading At last! A patient-centred statement on the proposed EU Clinical Trials Regulation
It has come to this. The world's top tennis players rush their shots to beat an 11pm curfew. Bruce and Sir Paul are turned-off mid-performance. And they don't use real javelins in schools. Looking across the the athletics field at my sons' school sports day, I spied a clutch of children competing in the javelin. Except this … Continue reading There is no point to the javelin
If you are interested in the EU Directive on Information to Patients, known colloquially in La Grande Place as 2001/83/EC, then this article from InPharm which went online this afternoon will get you up to speed with the latest changes made by the European Commission. The most significant of the three recent changes seems to … Continue reading European Commission makes further changes to Directive on Information to Patients
I mentioned yesterday about the EU Commission's plans to radically overhaul its approach to funding research and innovation. As expected these were launched in the form of a green paper today which is now open for public consultation until 20 May 2011. Quick summary as follows ( eGov also has quite a good overview). The … Continue reading EU plants green shoots of recovery
Science fear not. Those of you disappointed that the EU summit on 4th Feb only got round to the subject of 'innovation' at a late hour and to little discussion should take heart from the fact that patients have been used to being at the end of a conference/meeting agenda etc for most of the … Continue reading The NHS reforms and patients…and EU research shake-up?
The news that Pfizer is to close its R&D facility in Sandwich in Kent has shaken us from our sleepy winter hollows. I've been watching the reactions and comments come over the wires as I am sure you have. This is clearly a company going through considerable transition as it tries to change with the … Continue reading Pfizer…and innovation emergencies